Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom
Michele R. Wilson, Annika Bergman, Helene Chevrou-Severac, Ross Selby, Michael Smyth, Matthew C. Kerrigan
| Year of publication: |
March 2018
|
|---|---|
| Authors: | Wilson, Michele R. ; Bergman, Annika ; Chevrou-Severac, Helene ; Selby, Ross ; Smyth, Michael ; Kerrigan, Matthew C. |
| Published in: |
The European journal of health economics : HEPAC ; health economics in prevention and care. - Berlin : Springer, ISSN 1618-7598, ZDB-ID 2045253-6. - Vol. 19.2018, 2, p. 229-240
|
| Subject: | Ulcerative colitis | Vedolizumab | Costeffectiveness | Economics | Inflammatory bowel disease | Großbritannien | United Kingdom | Kosten-Wirksamkeits-Analyse | Cost-effectiveness analysis | Patienten | Patients | Vergleich | Comparison | Gesundheitskosten | Health care costs | Krankheit | Disease | Gesundheitswesen | Health care system | Gesundheitsökonomik | Health economics |